Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CreaVax-PC in Hormone-Refractory Metastatic Prostate Cancer
NCT01171729Phase 2Completed
- Sponsor
- Samsung Medical Center
- Start
- Jul 2006
- Primary completion
- May 2010
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of CreaVax-PC in prostate cancer (PCa), sponsored by Samsung Medical Center. Primary endpoints: PSA increment at 12 weeks and Absolute PSA response at 12 weeks. Started Jul 2006; status: completed.
02
Drugs
CreaVax-PC
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT01171729.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01171729.